Catalyst Event
AbbVie Inc (ABBV) · Other
From KEDI U.S. Medical AI Index (KUSMAI)
5/28/2026, 12:00:00 AM
U.S. FDA approved Decnupaz (pivekimab sunirine-pvzy), an ADC acquired via ImmunoGen, for adult BPDCN on 2026-05-28. High importance is estimated as the first ADC for this rare blood cancer, likely driving significant market impact.
Korean Translation
2026년 5월 28일, 미국 FDA가 희귀 혈액암인 BPDCN 치료를 위해 이뮤노젠 인수를 통해 확보한 최초의 ADC인 데크누파즈를 승인함. 최초 승인에 따른 상당한 시장 영향이 예상되어 중요도를 높게 평가함.
Related Recent Events
Tempus AI Inc (TEM) · Earnings Release
Tempus AI is scheduled to report its Q2 2026 financial results; earnings releases typically result in price moves of 5% or more, scheduled.
8/14/2026, 12:00:00 AM
BioNTech SE (BNTX) · Earnings Release
Next earnings release for Q2 2026 on 2026-08-03 is scheduled. Low importance is estimated for the scheduling announcement itself.
8/3/2026, 12:00:00 AM
AbbVie Inc (ABBV) · Earnings Release
Q2 2026 earnings release for 2026-07-30. Low importance as it is a routine announcement scheduled.
7/30/2026, 12:00:00 AM
Alphabet Inc (GOOGL) · Earnings Release
Alphabet's Q2 2026 earnings release is scheduled.
7/28/2026, 12:00:00 AM
Intuitive Surgical Inc (ISRG) · Earnings Release
Intuitive Surgical's Q2 2026 earnings release, a major stock catalyst, is scheduled.
7/21/2026, 12:00:00 AM
Recursion Pharmaceauticals Inc (RXRX) · Other
2026 Annual Meeting of Stockholders scheduled for June 17, 2026. Market reaction not yet occurred; low importance assigned due to likely <5% price impact from annual meeting scheduled.
6/17/2026, 12:00:00 AM